Full Text View
Tabular View
No Study Results Posted
Related Studies
Antihyperlipidemic Effects of Oyster Mushrooms
This study has been completed.
Study NCT00069524   Information provided by National Center for Complementary and Alternative Medicine (NCCAM)

First Received on September 29, 2003.   Last Updated on September 25, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Hyperlipidemia
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hyperlipidemias
More general conditions related to this trial
Dyslipidemias
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Lipid Metabolism Disorders
Metabolic Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
oyster mushroom
Additional drug interventions recognized in this trial
Hypolipidemic Agents
More general drug interventions related to this trial
Antimetabolites
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Center for Complementary and Alternative Medicine (NCCAM)
Office of Dietary Supplements (ODS)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services